BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1216 related articles for article (PubMed ID: 20571215)

  • 1. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.
    Amadoro G; Corsetti V; Stringaro A; Colone M; D'Aguanno S; Meli G; Ciotti M; Sancesario G; Cattaneo A; Bussani R; Mercanti D; Calissano P
    J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between NH(2)-tau fragment and Aβ in Alzheimer's disease mitochondria contributes to the synaptic deterioration.
    Amadoro G; Corsetti V; Atlante A; Florenzano F; Capsoni S; Bussani R; Mercanti D; Calissano P
    Neurobiol Aging; 2012 Apr; 33(4):833.e1-25. PubMed ID: 21958963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of tau in the development of Alzheimer's disease].
    Takashima A
    Brain Nerve; 2010 Jul; 62(7):701-8. PubMed ID: 20675874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
    Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
    Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Involvement of beta-amyloid in the etiology of Alzheimer's disease].
    Tomiyama T
    Brain Nerve; 2010 Jul; 62(7):691-9. PubMed ID: 20675873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex.
    van de Nes JA; Nafe R; Schlote W
    Brain Res; 2008 Jun; 1213():152-65. PubMed ID: 18455153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AD-linked, toxic NH2 human tau affects the quality control of mitochondria in neurons.
    Amadoro G; Corsetti V; Florenzano F; Atlante A; Ciotti MT; Mongiardi MP; Bussani R; Nicolin V; Nori SL; Campanella M; Calissano P
    Neurobiol Dis; 2014 Feb; 62():489-507. PubMed ID: 24411077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy.
    Cente M; Filipcik P; Pevalova M; Novak M
    Eur J Neurosci; 2006 Aug; 24(4):1085-90. PubMed ID: 16930434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease.
    Boche D; Donald J; Love S; Harris S; Neal JW; Holmes C; Nicoll JA
    Acta Neuropathol; 2010 Jul; 120(1):13-20. PubMed ID: 20532897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].
    Kuzuhara S
    Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
    Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M
    Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoaspartate formation and neurodegeneration in Alzheimer's disease.
    Shimizu T; Watanabe A; Ogawara M; Mori H; Shirasawa T
    Arch Biochem Biophys; 2000 Sep; 381(2):225-34. PubMed ID: 11032409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug development for tauopathy and Alzheimer's disease].
    Takashima A
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Aug; 30(4):177-80. PubMed ID: 20857696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo.
    Zilka N; Filipcik P; Koson P; Fialova L; Skrabana R; Zilkova M; Rolkova G; Kontsekova E; Novak M
    FEBS Lett; 2006 Jun; 580(15):3582-8. PubMed ID: 16753151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
    Padmanabhan J; Levy M; Dickson DW; Potter H
    Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease.
    Marcus JN; Schachter J
    J Neurogenet; 2011 Dec; 25(4):127-33. PubMed ID: 22091726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and Cellular Basis of Neurodegeneration in Alzheimer's Disease.
    Jeong S
    Mol Cells; 2017 Sep; 40(9):613-620. PubMed ID: 28927263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of calcium/calmodulin-dependent protein kinase II-alpha in the hippocampus of patients with Alzheimer's disease and its links with AD-related pathology.
    Wang YJ; Chen GH; Hu XY; Lu YP; Zhou JN; Liu RY
    Brain Res; 2005 Jan; 1031(1):101-8. PubMed ID: 15621017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.